News Column

CLOVIS ONCOLOGY, INC. FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits

September 2, 2014

Item 8.01 Other Events.

On September 2, 2014, the Clovis Oncology, Inc. (the "Company") issued a press release announcing its intention to offer $200 million aggregate principal amount of convertible senior notes due 2021, subject to market conditions and other factors, in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $30 million aggregate principal amount of such notes on the same terms and conditions. A copy of the Company's press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. This current report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy the notes.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits: 99.1 Press Release, dated September 2, 2014 - 2 -


For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters